BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 12, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Rho kinase inhibitors described in Chiesi Farmaceutici patent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Respiratory
Rho kinase inhibitors described in Chiesi Farmaceutici patent
July 17, 2023
No Comments
Chiesi Farmaceutici SpA has identified dihydrofuropyridine derivatives acting as Rho kinase 1 (ROCK1; p160-ROCK) and/or Rho kinase 2 (ROCK2; ROCKα) inhibitors.
BioWorld Science
Respiratory
Patents
